BRANFORD, Conn., Aug. 25, 2010 (GLOBE NEWSWIRE) -- CAS Medical Systems, Inc. (Nasdaq:CASM) today announced a new study to be published in the Canadian Journal of Anesthesia. The study from researchers in the Departments of Anesthesia and Surgery, at the University of Manitoba, Winnipeg, MB, Canada examined the correlation between a variety of point-of-care monitors and lactate flux, an indicator of metabolic stress during carotid endarterectomy (CEA). There are approximately 140,000 CEA procedures performed in the U.S. every year. The ability to assess the brain-at-risk during CEA under general anesthesia remains a major clinical challenge. A monitor that quickly alerts anesthesiologists in real-time of the potential for cerebral injury during CEA would be of considerable value to enhance the safety of this procedure. The authors note that "the ideal point-of-care monitor specific to anesthesia can accurately predict when an organ is at risk during an operative procedure so that a therapeutic intervention can be initiated to prevent further or permanent damage to that organ." The authors theorize that the body introduces lactate into the brain to serve as a critically important fuel for cerebral metabolism when the brain is faced with diminished oxygen supply, such as occurs during cross clamp in the CEA procedure. Results from this observational study suggest that large changes in cerebral tissue saturation (SctO2) as measured by the FORE-SIGHT ® Absolute Oximeter may provide a surrogate for measuring lactate changes during the CEA procedure. When assessing point-of-care monitors for correlation and identification of lactate changes, the authors suggest that the non-invasive FORE-SIGHT monitor may aid in the management of patients undergoing CEA during general anesthesia. Authors found that FORE-SIGHT Absolute Cerebral Oximetry "…correlated well with lactate flux – indicating the brain under stress." While FORE-SIGHT responded "within seconds" to lactate flux, the other tested point-of-care monitoring techniques (i.e., BIS, DSA and EEG) either failed to correlate or were very slow. The study concluded that alternative point-of-care monitors, such as processed EEG, either by EEGo or BIS, were "not quantitative enough or sensitive enough to indicate patients at risk."
Reference:Espenell AE, McIntyre IW, Gulati H, Girling LG, Wilkinson MF, Silvaggio JA, Koulack J, West M, Harding GE, Kaufmann AM, Mutch WA. Lactate flux during carotid endarterectomy under general anesthesia: correlation with various point-of-care monitors. Can J Anesth 2010 Jul 27. [Epub ahead of print] Abstract available at http://www.springerlink.com/content/d158331l25601552/ About CASMED® - Monitoring What's Vital CAS Medical Systems, Inc. is a leading developer and manufacturer of medical devices for non-invasive patient monitoring. The Company's FORE-SIGHT Absolute Cerebral Oximeter is the only cerebral oximeter available with FDA clearance for non-invasive, continuous measurement of absolute cerebral tissue oxygen saturation for all patients, regardless of age or weight. This information helps avert brain damage or death during surgery and in critical care situations by allowing clinicians to identify patients with dangerously low levels of cerebral oxygen and intervene to reverse the condition. The Company's product lines include the high-acuity monitoring capabilities of the FORE-SIGHT Cerebral Oximeter; the bedside patient monitoring line of vital signs monitoring products, proprietary non-invasive blood pressure measurement technology, and supplies and service including blood pressure cuffs and products for neonatal intensive care. CASMED products are designed to meet the needs of a full spectrum of patient populations worldwide, ranging from adults to pediatrics and neonates. For further information regarding CAS Medical Systems, Inc., visit the Company's website at www.casmed.com. The CAS Medical Systems, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=4675 Statements included in this press release, which are not historical in nature, are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Statements relating to the future financial performance of the Company are subject to many factors including, but not limited to, the customer acceptance of the products in the market, the introduction of competitive products and product development, the result of on-going litigation, working capital and availability of capital, commercialization and technological difficulties , the impact of actions and events involving key customers, vendors, lenders and competitors a nd other risks detailed in the Company's Form 10-K for the year ended December 31, 2009 and other subsequent Securities and Exchange Commission filings. Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. When used in this press release the terms "anticipate", "believe", "estimate", "expect", "may", "objective", "plan", "possible", "potential", "project", "will" and similar expressions identify forward-looking statements. The forward-looking statements contained in this press release are made as of the date hereof, and we do not undertake any obligation to update any forward-looking statements, whether as a result of future events, new information or otherwise.
CONTACT: CAS Medical Systems, Inc. Susan Carron, Director of Corporate Communications 203-488-6056 firstname.lastname@example.org